Heart Failure

Panelists discuss how heart failure creates a massive economic burden of approximately $30 billion annually (expected to reach $70 billion to $80 billion by 2030), driven by hospitalizations, readmissions, expensive multidrug regimens costing over $20,000 to $30,000 per patient, and high-cost interventions like ablations and advanced therapies.

The American Heart Association (AHA) launched a news initiative to address challenges with in-hospital care for patients with different types of heart failure.

The transthyretin cardiac amyloidosis (ATTR-CA) variant is more prevalent in Black individuals, increasing the need for more research to assess hereditary links and early prevention awareness.

Social determinants of health were associated with a younger age of first hospitalization for heart failure in Black and Hispanic patients when compared with Asian and White patients.

A new study evaluated real-world data on the efficacy of GLP-1s in patients with obesity and heart failure with preserved ejection fraction (HFpEF), confirming findings from prior research.

In an observational extension of the myPACE clinical trial, researchers found that a personalized accelerated pacing in patients with heart failure with preserved ejection fraction (HFpEF) and a preexisting physiological pacer saw a slower trend in adverse cardiac events and overall improved health status.

The analysis highlighted a shift in heart failure diagnoses, with hypertensive heart disease with and without chronic kidney disease as prevalent diagnoses, underlining coding variability and implications for research.

Clinical trial results establish the safety and efficacy of finerenone to help preserve potassium levels and reduce sodium in patients on diuretics with heart failure and mildly reduced ejection fraction or preserved ejection fraction.

The cause of dilated cardiomyopathy (DCM) can be associated with the presence of the TTN gene combined with preexisting comorbidities like atrial fibrillation, which increase the odds of developing DCM.

Left bundle branch block may serve as an important indicator for asymptomatic individuals predisposed to heart failure.

Explore innovative strategies to enhance heart failure treatment through guideline-directed medical therapy, remote monitoring, and artificial intelligence–driven solutions for better patient outcomes.

Black women had lower moderate-to-vigorous intensity physical activity scores when compared with Black and White men and their White female counterparts, highlighting the need for support across patient subgroups.

An AI model significantly outperformed cardiologists when reviewing ECGs of structural heart disease and may potentially be a step towards increased access and lower costs for early detection of conditions like heart failure and valvular heart disease.

The majority of patients with heart failure who qualified for sodium-glucose cotransporter 2 inhibitor (SGLT2i) therapy did not receive treatment; a recent study aims to find out why and measure prescription trends.

Social determinants of health significantly increased mortality risks in patients with congestive heart failure, highlighting urgent care needs.

Carpal tunnel syndrome was linked to wild-type transthyretin amyloidosis in new research, highlighting the importance of early diagnosis for better heart failure outcomes.

Finerenone gained FDA approval for heart failure treatment, showcasing significant benefits in reducing cardiovascular events, based on FINEARTS-HF trial results.

On December 10, 2024, cardiologists, researchers, and value-based care experts gathered in Dallas, Texas, to discuss best practices for implementing advances in cardiology care with a value-based mindset, spanning the care continuum from prevention to treatment.

Cardiologists, primary care physicians, and value-based care leaders convened in Phoenix, Arizona, on November 12, 2024, to share case studies and insights on how to align cardiology with the principles of value-based care, including through the application of digital tools.

Some of the top heart failure research looked at statins and semaglutide for heart failure with preserved ejection fraction, diabetes-related heart failure risks, and the protective cardiovascular effects of COVID-19 vaccination.

Health care conferences this year showcased advancements in treatments for chronic obstructive pulmonary disease and sleep apnea, discussions around health policy and economic research, and more.

Top coverage from the 2024 European Society of Cardiology (ESC) Congress focused on screening, treatment, and equity in cardiovascular care.

A SUMMIT trial analysis showed how tirzepatide improves cardiovascular and kidney health in patients with obesity-related heart failure with preserved ejection fraction (HFpEF).

Of the 518 hospitals that had at least 10 eligible discharges, only 11 of them prescribed SGLT2 inhibitors to more than half of their patients.

Noninvasive liver fibrosis scoring systems may help identify who is at risk of developing heart failure.